See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Resources Connection, Inc. (RGP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Resources Connection, Inc. (RGP) - free report >>
Image: Bigstock
New Strong Sell Stocks for January 11th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Carrols Restaurant Group, Inc. is a restaurant company in the United States. The Zacks Consensus Estimate for its current year earnings has been revised 33.3% downward over the last 30 days.
Enable Midstream Partners, LP is an owner, operator and developer of midstream energy infrastructure assets in the United States. The Zacks Consensus Estimate for its current year earnings has been revised 83.6% downward over the last 30 days.
The Greenbrier Companies, Inc. (GBX - Free Report) is a designer, manufacturer and marketer of railroad freight car equipment. The Zacks Consensus Estimate for its current year earnings has been revised 26.7% downward over the last 30 days.
Resources Connection, Inc. (RGP - Free Report) is a provider of consulting services to business customers. The Zacks Consensus Estimate for its current year earnings has been revised 34.9% downward over the last 30 days.
Champions Oncology, Inc. (CSBR - Free Report) is a developer of technology solutions and products to personalize the development and use of oncology drugs in the United States. The Zacks Consensus Estimate for its current year earnings has been revised 71.4% downward over the last 30 days.
View the entire Zacks Rank #5 List.